Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn’s disease

Daniel C Burger and Timothy H J Florin
Med J Aust 2009; 190 (6): . || doi: 10.5694/j.1326-5377.2009.tb02435.x
Published online: 16 March 2009

To the Editor: We read with great interest Drini and colleagues’ recent report of hepatosplenic T-cell lymphoma (HSTCL) associated with inflammatory bowel disease. The occurrence of this rare lymphoma is partly driving a move away from the use of combination thiopurine and anti-tumour necrosis factor alpha therapy. It is important to recognise that risk of HSTCL is not only associated with exposure to thiopurine drugs with or without infliximab. It is associated with immunocompromise in general, and also occurs de novo. Explaining relative risks to patients is never easy and needs to be balanced with the need for treatment in properly selected patients.

  • Daniel C Burger1
  • Timothy H J Florin1,2

  • 1 Department of Medicine, Mater Adult Hospital, Brisbane, QLD.
  • 2 University of Queensland, Brisbane, QLD.

Competing interests:

We both received travel assistance from Abbott and Schering-Plough to attend Digestive Disease Week 2008.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.